Most of the targeted drugs for HER-2 positive breast cancer are trastuzumab, others are patuzumab, lapatinib, neratinib, pyrrolitinib and so on.
Trastuzumab, a recombinant DNA-derived humanized monoclonal IgG type 1 antibody, selectively acts on the extracellular site of HER-2. It works by inhibiting HER-2 receptor activation, accelerating the internalization and degradation of the HER-2 protein receptor, and also enhances cellular attack and killing of tumor target cells through antibody-dependent cell-mediated cytotoxicity.
Adverse reactions include chest pain, muscle pain, dyspnea, etc. Use with caution in patients with poor cardiac function.
In the clinic, it is usually used in metastatic breast cancer with HER-2 overexpression. In primary breast cancer patients, about 25%-30% of patients have HER-2 overexpression, trastuzumab prepared by transgenic technology can reduce the risk of recurrence and metastasis in such breast cancer patients after surgery and improve disease-free survival.
If it is clear that the breast cancer is HER-2 positive, it is recommended to use targeted drugs as needed under the guidance of doctors in regular hospitals.